A detailed history of Caption Management, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Caption Management, LLC holds 126,200 shares of SNDX stock, worth $2.12 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
126,200
Holding current value
$2.12 Million
% of portfolio
0.04%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$17.93 - $24.81 $364,445 - $504,288
20,326 New
20,326 $391,000
Q3 2023

Nov 14, 2023

SELL
$14.52 - $21.77 $36,270 - $54,381
-2,498 Reduced 21.17%
9,302 $135,000
Q2 2023

Aug 14, 2023

SELL
$19.35 - $22.31 $61,920 - $71,392
-3,200 Reduced 21.33%
11,800 $246,000
Q1 2023

May 15, 2023

BUY
$20.66 - $28.98 $309,900 - $434,700
15,000 New
15,000 $316,000
Q1 2022

May 13, 2022

SELL
$14.84 - $22.15 $685,993 - $1.02 Million
-46,226 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$15.23 - $22.47 $704,021 - $1.04 Million
46,226 New
46,226 $1.01 Million
Q3 2021

Nov 12, 2021

SELL
$13.87 - $19.8 $272,254 - $388,654
-19,629 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$13.42 - $25.18 $447,838 - $840,281
-33,371 Reduced 62.96%
19,629 $337,000
Q1 2021

May 17, 2021

BUY
$19.28 - $24.59 $385,600 - $491,800
20,000 Added 60.61%
53,000 $1.19 Million
Q4 2020

Feb 16, 2021

BUY
$15.1 - $26.44 $330,478 - $578,665
21,886 Added 196.92%
33,000 $733,000
Q3 2020

Nov 16, 2020

BUY
$13.39 - $17.48 $142,121 - $185,532
10,614 Added 2122.8%
11,114 $164,000
Q3 2019

Nov 14, 2019

BUY
$7.47 - $10.76 $3,735 - $5,380
500 New
500 $4,000
Q1 2019

May 14, 2019

SELL
$4.26 - $6.86 $360,677 - $580,808
-84,666 Closed
0 $0
Q4 2018

Jan 30, 2019

BUY
$3.6 - $8.42 $117,597 - $275,047
32,666 Added 62.82%
84,666 $377,000
Q3 2018

Nov 14, 2018

BUY
$6.33 - $8.08 $329,160 - $420,160
52,000 New
52,000 $421,000

Others Institutions Holding SNDX

About Syndax Pharmaceuticals Inc


  • Ticker SNDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,565,200
  • Market Cap $950M
  • Description
  • Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...
More about SNDX
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.